Edgewise Therapeutics, Inc. $EWTX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING1
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Sevasemten Dose 1 NCT05540860 |
P2 | Active, not recruiting | Duchenne Muscular Dystrophy | 76 | 2027-01 (+31 mo) |
| FOX NCT06100887 |
P2 | Active, not recruiting | Duchenne Muscular Dystrophy | 43 | 2027-03 (+21 mo) |
| EQUINOX NCT07795814 |
P2 | Recruiting | Heart Failure With Preserved Ejection Fraction | 90 | 2027-12 |
| EDG-7500 NCT06347159 |
P2 | Active, not recruiting | Hypertrophic Cardiomyopathy | 79 | 2027-12 (+33 mo) |
| MESA NCT06066580 |
P2 | Enrolling by invitation | Becker Muscular Dystrophy | 260 | 2031-02 (+35 mo) |